Physician profile
Casey Bowe
NPI 1023578077
$2,405.63
in general payments reported to CMS, 2019-2025
24 companies · $822 in 2025
The $822 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $270 · 2023: $624 · 2024: $689 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,135.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $456.87 | 2023-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $434.26 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceutical Holding Company Ltd. | $257.84 | 2022 | |
| Lilly USA, LLC | $237.27 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $196.71 | 2024-2025 | Repatha, Evenity, Otezla |
| Exact Sciences Corporation | $125.10 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $110.93 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $99.08 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $68.42 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $63.53 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $52.60 | 2023-2024 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $45.73 | 2023-2024 | Rexulti |
| Dynavax Technologies Corporation | $40.77 | 2024-2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals Lp | $40.46 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Sumitomo Pharma America, INC. | $25.17 | 2024 | Gemtesa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $22.16 | 2025 | Neurostar Tms Therapy System |
| Viiv Healthcare Company | $21.00 | 2025 | Apretude |
| Halozyme INC | $17.51 | 2023 | |
| Antares Pharma, INC. | $16.70 | 2025 | Xyosted |
| Medtronic, INC. | $15.75 | 2025 | Minimed 780g |
| Idorsia Pharmaceuticals US INC | $15.46 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $15.22 | 2024 | |
| Radius Health, INC. | $14.85 | 2025 | Tymlos |
| Kowa Pharmaceuticals America, INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Bowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.